BioMedNewsBreaks

FridayAug 07, 2026 2:59 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones

Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory and commercial milestones amid growing interest in regenerative orthopedic solutions. GelrinC is an off-the-shelf, cell-free implant designed for a streamlined, single-step procedure that supports cartilage regeneration without the cell harvesting and laboratory processing required by some alternative approaches. Regentis is continuing enrollment in its U.S. clinical study, preparing for a potential FDA Premarket Approval submission, expanding commercialization efforts in Europe following CE Mark approval, and optimizing manufacturing for scalability and consistency. To view the full article, visit https://ibn.fm/mVCsB About Regentis Biomaterials Ltd. Regentis Biomaterials is a…

Continue Reading

FridayAug 07, 2026 2:16 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Two-Pronged Approach to Neurological Health

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, is developing a two-pronged strategy addressing neurological health through its investigational multiple sclerosis therapy Lucid-MS and its proprietary dietary supplement unbuzzd. Lucid-MS is designed to target PAD2, an enzyme associated with myelin degradation, with the goal of protecting and potentially restoring the myelin sheath rather than primarily modulating the immune system. The company submitted an IND application to the FDA for a Phase 2 trial and is supporting development through an imaging collaboration…

Continue Reading

FridayAug 07, 2026 1:21 pm

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Builds Strategic Position in Antibody Therapeutics Market

VERAXA Biotech (NASDAQ: VRXA) is developing next-generation antibody therapeutics across antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”), two areas that continue to attract significant pharmaceutical investment. A recent article highlights major transactions to illustrate how differentiated antibody-engineering platforms can attract substantial financial commitments even before clinical development reaches advanced stages. VERAXA’s proprietary BiTAC platform supports a pipeline that includes bispecific ADCs, T-cell engagers and engineered antibody formats, potentially creating opportunities for future platform partnerships, licensing agreements or asset-level transactions. To view the full article, visit https://ibn.fm/sMjlp About VERAXA Biotech AG VERAXA is building a premier engine for the discovery and development of…

Continue Reading

FridayAug 07, 2026 9:20 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Reports 57% Increase in Fiscal First-Quarter Net Income

Earth Science Tech (OTC: ETST) reported fiscal first-quarter 2027 results highlighted by a 57% year-over-year increase in net income to $715,697 on revenue of $9.0 million, up 3% from the prior-year period. Gross profit rose to $6.3 million, operating cash flow more than doubled to $707,131 and total assets increased to $10.4 million. Diluted earnings per share improved to $0.003 from $0.001, while the company repurchased and retired more than 3.7 million common shares during the quarter without adding debt. The company said all key operating subsidiaries remained profitable as it continued expanding the licensing footprint of its compounding pharmacy…

Continue Reading

WednesdayAug 05, 2026 1:17 pm

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) Combines Targeted Cancer Therapy, Nanotechnology and AI

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is pursuing an integrated approach to cancer drug development that combines three emerging areas: PNKP-targeted DNA damage response (“DDR”) inhibition, nanoparticle drug delivery and artificial intelligence. Its lead candidate, ONC010, pairs a PNKP inhibitor with a polymer micelle carrier intended to improve drug solubility, tumor accumulation and tolerability, while the company’s Inka Health subsidiary is developing the SynoGraph causal AI platform to support patient selection, clinical trial design and evidence generation. The company is advancing ONC010 through preclinical, manufacturing and IND-enabling activities, with plans…

Continue Reading

WednesdayAug 05, 2026 12:55 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Advances Telehealth Position Through Technology, Vertical Integration

Earth Science Tech (OTC: ETST) was featured in a recent article that discussed its positioning in the growing telehealth and healthcare markets through strategic investments, vertical integration and proprietary technology. Through subsidiaries such as DOConsultations LLC and Las Villas Health Care Inc., the company provides online and brick-and-mortar telehealth services focused on wellness and direct-to-patient delivery, while also targeting the expanding peptide therapy market. ETST’s in-house IT capabilities and custom technology infrastructure are designed to provide a competitive advantage by improving operational efficiency and margins across its divisions. As the company continues expanding its technology and healthcare offerings, its integrated platform…

Continue Reading

WednesdayAug 05, 2026 12:26 pm

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Publishes Peer-Reviewed Capture-Seq Study 

VolitionRx Limited (NYSE American: VNRX) announced the publication of the first peer-reviewed paper detailing its proprietary Capture-Seq liquid biopsy technology, which the company said is the first to isolate and analyze more than 99% pure circulating tumor-derived DNA ("ctDNA"). According to the publication, the technology addresses a longstanding challenge in liquid biopsy by separating cancer-derived DNA from the large background of healthy cell-free DNA, creating highly enriched tumor DNA datasets for cancer detection and monitoring. Volition said it is conducting technical evaluations with potential licensing partners and estimates the technology addresses annual market opportunities of approximately $23 billion for multi-cancer early detection and more than $13 billion for…

Continue Reading

TuesdayAug 04, 2026 1:25 pm

BioMedNewsBreaks — SRX Global Inc. (NYSE American: SRXH) Acquires Stake in Vistagen Therapeutics 

SRX Global (NYSE American: SRXH) announced that it has acquired a stake in Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company developing intranasal neuroscience therapies based on its proprietary pherine platform. SRX said the investment aligns with its strategy of creating long-term shareholder value through investments in high-conviction operating companies and strategic assets. SRX said it believes Vistagen shares are undervalued and intends to engage constructively with the company's leadership team and board of directors to discuss opportunities to unlock shareholder value. To view the full press release, visit https://ibn.fm/VFyBI About SRX Global Inc. SRX Global is an AI-driven platform focused on generating long-term shareholder value through investments in high-conviction…

Continue Reading

MondayAug 03, 2026 9:50 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Present at OTCQB Virtual Investor Conference

Oncotelic Therapeutics (OTCQB: OTLC) announced that CEO and Chairman Dr. Vuong Trieu will present at the OTCQB Virtual Investor Conference on Aug. 6, 2026, at 2:30 p.m. ET, where investors will have the opportunity to participate in a live question-and-answer session. The company will highlight recent progress, including advancement of its Phase 1b intravenous Everolimus (Sapu003) trial to the next dose cohort, expansion of European clinical sites, validation of its Deciparticle(TM) platform through peer-reviewed publications, scalable cGMP manufacturing capabilities and continued development of its AI-driven drug discovery, robotics and nanomedicine platforms. To view the full press release, visit https://ibn.fm/fGHUt About…

Continue Reading

FridayJul 31, 2026 3:53 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances Regenerative Solution for Major Unmet Need in Cartilage Repair

Regentis Biomaterials (NYSE American: RGNT) was featured in a recent article that discussed its efforts to advance GelrinC, a potentially first-in-class, off-the-shelf cartilage regeneration platform, and the company’s broader mission to establish a new standard of care in cartilage repair. “Regentis is developing regenerative biomaterial technology as healthcare shifts toward therapies designed to restore damaged tissue rather than simply manage symptoms. With cartilage defects affecting hundreds of thousands of patients each year and contributing to pain, reduced mobility, and degenerative joint disease, the company is targeting one of orthopedic medicine’s largest unmet needs,” reads the article. “GelrinC’s commercial potential is rooted in…

Continue Reading